Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Interleukin-4 receptor alpha antagonist (monoclonal antibody)

Dupixent (dupilumab)

An approved treatment for Eosinophilic Esophagitis and Bullous Pemphigoid.

FDA Approved (2017)by Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. (manufactured by Regeneron)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2017

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Dupilumab wherever you encounter it, plus the key facts at a glance.

Generic name
Dupilumab
Brand name
Dupixent
Development codes
REGN668, SAR231893
Drug class
Interleukin-4 receptor alpha antagonist (monoclonal antibody)
Manufacturer
Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. (manufactured by Regeneron)
How it's taken
Injection under the skin, every week or every 2 weeks depending on use and weight

An antibody injected under the skin that is FDA approved for eosinophilic esophagitis (EoE) in people 1 year and older who weigh at least 15kg, and for bullous pemphigoid in adults[1].

  • The FDA approved Dupixent for EoE in May 2022, widened that use to children 1 to 11 in January 2024, and approved it for bullous pemphigoid in June 2025[2].
  • Dupixent has no boxed warning[1].
  • The Dupixent label also covers atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, COPD, chronic spontaneous urticaria and allergic fungal rhinosinusitis, which this page does not cover[1].
Follow Dupixent by email

We'll email you when Dupixent's FDA label changes, when the FDA acts on it, and when new trials for the condition you pick open. Unsubscribe anytime.

You'll get, for Eosinophilic Esophagitis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Dupilumab fits

Dupixent (dupilumab) is an injected antibody that blocks IL-4 and IL-13 signaling, approved for eosinophilic esophagitis in people 1 and older who weigh at least 15kg and for bullous pemphigoid in adults[1].

  • For eosinophilic esophagitis, the 2020 AGA and Joint Task Force guideline recommends swallowed topical steroids and also suggests proton pump inhibitors, elimination or elemental diets, and dilation of a narrowed esophagus in adults[11].
  • Eohilia (budesonide oral suspension) is the other FDA-approved eosinophilic esophagitis medicine, a swallowed steroid labeled for a 12-week course in people 11 and older[10]. Neither the Dupixent label nor the Eohilia label reports a trial comparing the 2 drugs in eosinophilic esophagitis, and the one registered comparison is a small early-phase Mayo Clinic study with no results posted[9].
  • For bullous pemphigoid, NORD describes strong steroid creams for limited disease, steroid pills such as prednisone for more widespread disease, and steroid-sparing medicines added early to limit steroid use[12].
  • Sanofi describes Dupixent as the only targeted medicine approved in the US for bullous pemphigoid, and the Dupixent label pairs it with a tapering course of oral steroids rather than replacing them at the start[5][1].
  • The bullous pemphigoid trial ADEPT compared Dupixent with placebo on top of steroids, and no registered trial compares Dupixent with another bullous pemphigoid medicine[8].
  • Anyone weighing Dupixent for eosinophilic esophagitis or bullous pemphigoid can ask their gastroenterologist or dermatologist how a response would be measured and which eye symptoms to report.

How Dupilumab works

In eosinophilic esophagitis, allergy-type white blood cells called eosinophils build up in the lining of the esophagus, the tube that carries food to the stomach, and in bullous pemphigoid the immune system attacks proteins that anchor the top layer of skin, causing blisters and itching. The Dupixent label says inflammation driven by 2 immune messengers, interleukin-4 (IL-4) and interleukin-13 (IL-13), is an important part of both diseases[1].

Dupilumab is a human antibody that attaches to IL-4R alpha, a receptor piece the IL-4 and IL-13 receptors share, which blocks both signals[1]. Blocking that receptor cuts the release of other inflammatory messengers, chemokines, nitric oxide and the allergy antibody IgE, though the label says the exact way dupilumab works has not been definitively established[1].

Dupixent is an antibody, not a steroid[1]. Its label warns about parasitic worm infections and says to avoid live vaccines during treatment[1].

Side effects and safety

What patients report
Label warnings
  • Allergic reactions. anaphylaxis, serum sickness, angioedema, hives, rash, erythema nodosum, erythema multiforme and acute generalized exanthematous pustulosis (AGEP), a sudden rash of small pus bumps, have occurred; 1 adult in the bullous pemphigoid program had AGEP, and the label says to stop Dupixent after a serious reaction
  • Eye inflammation (conjunctivitis, keratitis, blepharitis). in the bullous pemphigoid trial, 8% had conjunctivitis and 4% keratitis against 0% on placebo; no cases were reported on Dupixent in the placebo-controlled EoE trials, and 4% of children had conjunctivitis in the EoE-2 extension; the label asks patients to report new or worse eye symptoms
  • Eosinophilic conditions. eosinophilic pneumonia and EGPA, a blood vessel inflammation, have occurred, mainly in the asthma program, sometimes as steroid doses came down; signs include a vasculitic rash, worse breathing, heart or kidney problems and nerve symptoms
  • Stopping steroids suddenly. the label says steroid pills, creams or inhalers should not be stopped abruptly when Dupixent starts, and that any reduction is gradual and under a doctor's direction
  • Not for sudden asthma or COPD attacks. the label says Dupixent does not treat acute asthma or COPD symptoms, and that people with asthma should not change their asthma medicines without talking to their doctor
  • New psoriasis. reported weeks to months after starting, including in people with no family history
  • Joint pain and psoriatic arthritis. joint pain, sometimes with trouble walking and some hospital stays, and new psoriatic arthritis have been reported
  • Parasitic (helminth) infections. existing worm infections are treated before starting; 1 child had a worm infection during the EoE-2 extension
  • Vaccines. age-appropriate vaccines are ideally finished before starting, and live vaccines are avoided during treatment
  • Pregnancy and breastfeeding. case reports have not shown a drug-linked risk of birth defects or miscarriage, antibodies like dupilumab cross the placenta, and there is a pregnancy exposure registry; there are no data on dupilumab in breast milk
Most common in trials
Injection site reactionsUpper respiratory infectionsJoint painHerpes infections such as cold soresConjunctivitisBlurred visionKeratitis
What gets monitored
  • Eye symptoms such as redness, itching, pain or vision changes, with an eye exam when they do not clear
  • Joint pain and any new psoriasis
  • Rash, breathing changes or nerve symptoms that could signal an eosinophilic condition, especially while steroids are being lowered
  • Vaccines brought up to date before starting
  • For bullous pemphigoid, the oral steroid taper agreed with the doctor
Report a suspected reaction to Regeneron at 1-844-387-4936, or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
Side effects in the trial, Dupixent against placebo
DupixentPlaceboShare of people in each group who reported it
Injection site reactions
38%
33%
Upper respiratory infections
18%
10%
Joint pain
2%
1%
Herpes infections such as cold sores
2%
1%
Bars run from 0% to 40%. A side effect can be more common in the placebo group, which can happen when the symptom comes from the disease itself or by chance.
In context

Dupixent has no boxed warning[1]. Its label warns about allergic reactions including anaphylaxis and a pustular rash called AGEP, eye inflammation (conjunctivitis, keratitis and blepharitis, with some vision loss reported after approval), eosinophilic conditions such as eosinophilic pneumonia and EGPA, problems from stopping steroids suddenly, new psoriasis, joint pain and psoriatic arthritis, and parasitic worm infections, and it says to avoid live vaccines[1].

In eosinophilic esophagitis, in the 24-week EoE-1 trial of 122 people 12 and older on Dupixent 300mg weekly and 117 on placebo, side effects in at least 2% and more common than placebo were injection site reactions (38% against 33%), upper respiratory infections (18% against 10%), joint pain (2% against 1%) and herpes infections such as cold sores (2% against 1%)[1].

Side effects led 2% in each group to stop treatment, and no conjunctivitis or keratitis was reported on Dupixent in the placebo-controlled EoE trials[1]. The label says safety in 61 children 1 to 11 was generally similar, with 4% conjunctivitis and 1 worm infection during the 36-week extension[1].

In bullous pemphigoid, in the ADEPT trial of 53 adults on Dupixent and 53 on placebo, all also taking a tapering course of oral steroids, side effects in at least 2% and more common than placebo were joint pain (9% against 6%), conjunctivitis (8% against 0%), blurred vision (8% against 0%), herpes infections including shingles (6% against 0%) and keratitis (4% against 0%)[1].

Shingles alone was reported in 4% on Dupixent and 0% on placebo, 1 person on Dupixent had AGEP, and a high eosinophil count of 500 cells/mcL or more was more common on Dupixent (21% against 11%)[1]. Of the 53 people with bullous pemphigoid on Dupixent, 40 were 65 or older, and 10% of those older adults had blurred vision against none of the younger adults[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Dupilumab

Dupixent is a shot under the skin of the thigh or belly, avoiding 2 inches around the navel, or the upper arm when a caregiver gives it, with the site changed each time[1]. For eosinophilic esophagitis the dose is set by body weight, with no starting double dose: 200mg every 2 weeks for 15kg to under 30kg, 300mg every 2 weeks for 30kg to under 40kg, and 300mg every week for 40kg or more[1].

For bullous pemphigoid in adults the dose is 600mg on the first day, given as two 300mg shots at different sites, then 300mg every other week, together with a tapering course of oral steroids. The label says that once the disease is under control the steroids are tapered and Dupixent continues alone, and that steroids may be added back for a relapse if medically advisable[1].

The prefilled pen is for ages 2 and up and the prefilled syringe for 6 months and up; people 12 and older may inject themselves with an adult supervising teens, and a caregiver gives the shot to children under 12[1]. A missed weekly dose is given as soon as possible and starts a new weekly schedule; a missed every-2-week dose is given within 7 days and the original schedule resumes[1].

Dupixent is kept in the refrigerator at 2°C to 8°C (36°F to 46°F) in its carton, can stay at room temperature up to 25°C (77°F) for at most 14 days, and is never frozen or shaken. Before a shot it warms up for 45 minutes (300mg) or 30 minutes (200mg)[1]. Dupixent comes as 300mg/2mL and 200mg/1.14mL prefilled pens and syringes in cartons of 2[1].

The label says an effect on the levels of other medicines is not expected, and in a study of 5 common liver-processed drugs no clinically significant changes were seen[1].

Availability and cost

No generic available

Only available as the brand-name product.

Why it costs what it costs

A biologic injected every week or every 2 weeks, sold in cartons of 2 prefilled pens or syringes. The Dupixent website gives a list price of $4,193.03 per carton as of January 2, 2026 and says most people will not pay the list price[13]. At the weekly eosinophilic esophagitis dose for people 40kg and up, 1 carton covers 2 weeks. The DUPIXENT MyWay copay card covers up to $13,000 a year for eligible commercially insured patients[14].

Help paying for Dupixent

With private insurance, the drugmaker's copay card can lower what you pay for Dupixent. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 2 charity funds for the conditions it treats, 1 was open on November 16, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Dupixent (Dupilumab)
Some details not published
  • Copay help

    DUPIXENT MyWay Copay Card: eligible patients with commercial insurance, including health insurance exchanges, federal employee plans and state employee plans, may pay as little as $0 per fill, up to $13,000 per patient per calendar year. Not valid for prescriptions paid in whole or in part by Medicaid, Medicare, VA, DOD, TRICARE or other federal or state programs, including state pharmaceutical assistance programs. Approval is not guaranteed.

    For: private insurance · source
  • Free medicine program

    DUPIXENT MyWay Patient Assistance Program: for people without health insurance, people having difficulty paying and people with Medicare Part D. A DUPIXENT MyWay Case Manager reviews eligibility case by case, including household income; no income limit is published.

    For: no insurance, underinsured · source
  • Insurance and case manager help

    DUPIXENT MyWay: call 1-844-DUPIXENT (1-844-387-4936), option 1, Monday to Friday, 8 AM to 9 PM ET.

    The official page does not say who qualifies. Ask the program. · source

Good to know: Read on dupixent.com (copay-card, cost-insurance and the nasal polyps copay FAQ pages) on November 19, 2026. The copay-card page says only 'subject to the program maximum'; the $13,000 cap is from the FAQ page. No income limit is published.

Checked on the drugmaker's official pages on November 19, 2026. Programs change; confirm with the program before you rely on it.

Charity funds

  • From a charity · TotalAssist (formerly PAN Foundation)
    Eosinophilic Esophagitis fund
    Open

    Pays for: Out-of-pocket costs for approved medications, up to $2,000 per year. Requires Medicare, Medicaid or TRICARE.

  • From a charity · The Assistance Fund
    Eosinophilic Esophagitis fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and charity fund for Eosinophilic Esophagitis →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Access and eligibility

Manufacturer
Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals, Inc.
Eligibility requirement

Eosinophilic esophagitis: approved for adults and children 1 year and older who weigh at least 15kg; safety and effectiveness have not been established under age 1 or under 15kg[1]. The EoE trials enrolled people whose biopsies still showed active disease after a proton pump inhibitor course[1]. Bullous pemphigoid: approved for adults, given with a tapering course of oral steroids; safety and effectiveness in children have not been established[1]. Dupixent is not used by people with a known allergy to dupilumab or its ingredients[1].

Source: DUPIXENT MyWay

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Clinical trial results

Eosinophilic esophagitis, ages 12 and up: Study EoE-1 (NCT03633617) enrolled people weighing at least 40kg whose biopsies still showed 15 or more eosinophils per high-power field after a proton pump inhibitor course, in 2 separate 24-week parts comparing Dupixent 300mg weekly with placebo[1][6]. Histologic remission, 6 or fewer eosinophils per high-power field, was reached by 59.5% on Dupixent against 5.1% on placebo in Part A (42 and 39 people) and 58.8% against 6.3% in Part B (80 and 79 people)[1].

Scores on the Dysphagia Symptom Questionnaire, a 0 to 84 swallowing scale where lower is better, fell by 21.9 points against 9.6 in Part A and 23.8 against 13.9 in Part B[1]. Eosinophilic esophagitis, ages 1 to 11: Study EoE-2 (EoE KIDS, NCT04394351) tested weight-based doses of 200mg or 300mg every 2 weeks against placebo for 16 weeks in children weighing at least 15kg, and 65.6% on Dupixent reached histologic remission against 3.4% on placebo (32 and 29 children)[1][7].

The label notes that the 300mg every-2-week dose tested is lower than today's weekly dose for children 40kg and up, which rests on drug-level modeling, and that at week 52, 17 of 32 children on Dupixent throughout were in remission[1]. Bullous pemphigoid: ADEPT (LIBERTY-BP, NCT04206553), a 52-week Phase 2/3 trial, randomized 106 adults with moderate-to-severe disease to Dupixent or placebo, all also starting prednisone or prednisolone that was tapered with the aim of stopping by week 16[1][8][5].

Sustained remission at week 36, meaning complete remission off steroids by week 16 with no relapse or rescue treatment, was reached by 18.3% on Dupixent against 6.1% on placebo. The label's 95% confidence interval for that 12.2-point difference runs from -0.8 to 26.1, which includes no difference[1]. A drop of at least 4 points in itch on a 0 to 10 scale was seen in 38.3% against 10.5% (difference 27.8, interval 11.6 to 43.4)[1].

The median total steroid dose by week 36 was 2.8g on Dupixent against 4.1g on placebo, and 53% against 79% needed rescue treatment[1]. The average ADEPT participant was 71.3 years old, and 63% had already taken systemic steroids for bullous pemphigoid[1].

Development history

Regeneron and Sanofi developed dupilumab together[3], under the codes REGN668 and SAR231893[6]. The FDA first approved Dupixent on March 28, 2017 under BLA 761055[2]. The FDA approved Dupixent 300mg weekly for eosinophilic esophagitis in people 12 and older weighing at least 40kg on May 20, 2022, and Sanofi said the approval came more than 2 months ahead of the priority review action date[2][3].

On January 25, 2024 the FDA extended the eosinophilic esophagitis use to children 1 to 11 who weigh at least 15kg[2][4]. On June 18, 2025 the FDA approved Dupixent for adults with bullous pemphigoid after a priority review, and Sanofi said the FDA had earlier granted orphan drug designation for the disease[2][5]. The current label, revised in April 2026, lists 9 uses[1].

Ask anything about Dupilumab
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Eosinophilic Esophagitis and Bullous Pemphigoid trials

Other Eosinophilic Esophagitis & Bullous Pemphigoid treatments

Common questions about Dupilumab

▸What is Dupilumab (Dupixent)?

An antibody injected under the skin that is FDA approved for eosinophilic esophagitis (EoE) in people 1 year and older who weigh at least 15kg, and for bullous pemphigoid in adults[1]. The FDA approved Dupixent for EoE in May 2022, widened that use to children 1 to 11 in January 2024, and approved it for bullous pemphigoid in June 2025[2]. Dupixent has no boxed warning[1]. The Dupixent label also covers atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, COPD, chronic spontaneous urticaria and allergic fungal rhinosinusitis, which this page does not cover[1].

▸How does Dupilumab work?

In eosinophilic esophagitis, allergy-type white blood cells called eosinophils build up in the lining of the esophagus, the tube that carries food to the stomach, and in bullous pemphigoid the immune system attacks proteins that anchor the top layer of skin, causing blisters and itching. The Dupixent label says inflammation driven by 2 immune messengers, interleukin-4 (IL-4) and interleukin-13 (IL-13), is an important part of both diseases[1]. Dupilumab is a human antibody that attaches to IL-4R alpha, a receptor piece the IL-4 and IL-13 receptors share, which blocks both signals[1]. Blocking that receptor cuts the release of other inflammatory messengers, chemokines, nitric oxide and the allergy antibody IgE, though the label says the exact way dupilumab works has not been definitively established[1]. Dupixent is an antibody, not a steroid[1]. Its label warns about parasitic worm infections and says to avoid live vaccines during treatment[1].

▸What are the side effects of Dupilumab?

Dupixent has no boxed warning[1]. Its label warns about allergic reactions including anaphylaxis and a pustular rash called AGEP, eye inflammation (conjunctivitis, keratitis and blepharitis, with some vision loss reported after approval), eosinophilic conditions such as eosinophilic pneumonia and EGPA, problems from stopping steroids suddenly, new psoriasis, joint pain and psoriatic arthritis, and parasitic worm infections, and it says to avoid live vaccines[1]. In eosinophilic esophagitis, in the 24-week EoE-1 trial of 122 people 12 and older on Dupixent 300mg weekly and 117 on placebo, side effects in at least 2% and more common than placebo were injection site reactions (38% against 33%), upper respiratory infections (18% against 10%), joint pain (2% against 1%) and herpes infections such as cold sores (2% against 1%)[1]. Side effects led 2% in each group to stop treatment, and no conjunctivitis or keratitis was reported on Dupixent in the placebo-controlled EoE trials[1]. The label says safety in 61 children 1 to 11 was generally similar, with 4% conjunctivitis and 1 worm infection during the 36-week extension[1]. In bullous pemphigoid, in the ADEPT trial of 53 adults on Dupixent and 53 on placebo, all also taking a tapering course of oral steroids, side effects in at least 2% and more common than placebo were joint pain (9% against 6%), conjunctivitis (8% against 0%), blurred vision (8% against 0%), herpes infections including shingles (6% against 0%) and keratitis (4% against 0%)[1]. Shingles alone was reported in 4% on Dupixent and 0% on placebo, 1 person on Dupixent had AGEP, and a high eosinophil count of 500 cells/mcL or more was more common on Dupixent (21% against 11%)[1]. Of the 53 people with bullous pemphigoid on Dupixent, 40 were 65 or older, and 10% of those older adults had blurred vision against none of the younger adults[1].

▸How is Dupilumab taken?

Dupixent is a shot under the skin of the thigh or belly, avoiding 2 inches around the navel, or the upper arm when a caregiver gives it, with the site changed each time[1]. For eosinophilic esophagitis the dose is set by body weight, with no starting double dose: 200mg every 2 weeks for 15kg to under 30kg, 300mg every 2 weeks for 30kg to under 40kg, and 300mg every week for 40kg or more[1]. For bullous pemphigoid in adults the dose is 600mg on the first day, given as two 300mg shots at different sites, then 300mg every other week, together with a tapering course of oral steroids. The label says that once the disease is under control the steroids are tapered and Dupixent continues alone, and that steroids may be added back for a relapse if medically advisable[1]. The prefilled pen is for ages 2 and up and the prefilled syringe for 6 months and up; people 12 and older may inject themselves with an adult supervising teens, and a caregiver gives the shot to children under 12[1]. A missed weekly dose is given as soon as possible and starts a new weekly schedule; a missed every-2-week dose is given within 7 days and the original schedule resumes[1]. Dupixent is kept in the refrigerator at 2°C to 8°C (36°F to 46°F) in its carton, can stay at room temperature up to 25°C (77°F) for at most 14 days, and is never frozen or shaken. Before a shot it warms up for 45 minutes (300mg) or 30 minutes (200mg)[1]. Dupixent comes as 300mg/2mL and 200mg/1.14mL prefilled pens and syringes in cartons of 2[1]. The label says an effect on the levels of other medicines is not expected, and in a study of 5 common liver-processed drugs no clinically significant changes were seen[1].

▸Is Dupilumab FDA approved?

Yes. Dupixent is FDA approved for eosinophilic esophagitis in people 1 year and older who weigh at least 15kg, and for bullous pemphigoid in adults.

EoE, ages 12 and up: approved May 20, 2022 for people weighing at least 40kg.

EoE, ages 1 to 11: added January 25, 2024 for children weighing at least 15kg.

Bullous pemphigoid: approved June 18, 2025 for adults, given with a tapering course of oral steroids.

First approval: March 28, 2017; the label also covers atopic dermatitis, asthma, nasal polyps, prurigo nodularis, COPD, chronic spontaneous urticaria and allergic fungal rhinosinusitis.

Source: Dupixent prescribing information and Drugs@FDA BLA 761055

▸What is the Dupixent dose for eosinophilic esophagitis?

The eosinophilic esophagitis dose depends on body weight, with no starting double dose[1].

15kg to under 30kg: 200mg every 2 weeks.

30kg to under 40kg: 300mg every 2 weeks.

40kg or more: 300mg every week.

Missed weekly dose: given as soon as possible, then a new weekly schedule starts from that day.

Source: Dupixent prescribing information

▸How well does Dupixent work for EoE?

In the EoE-1 trial of people 12 and older, about 59% on Dupixent reached histologic remission at 24 weeks, against 5-6% on placebo[1].

Part A: 59.5% against 5.1%.

Part B: 58.8% against 6.3%.

Swallowing: Dysphagia Symptom Questionnaire scores fell by 21.9 and 23.8 points on Dupixent against 9.6 and 13.9 on placebo.

Children 1 to 11: 65.6% against 3.4% at 16 weeks in EoE-2.

Source: Dupixent prescribing information

▸Is Dupixent approved for bullous pemphigoid?

Yes. The FDA approved Dupixent for adults with bullous pemphigoid on June 18, 2025[2].

Dose: 600mg on day 1, then 300mg every other week.

With steroids: the label pairs it with a tapering course of oral steroids, then Dupixent continues alone once the disease is controlled.

Children: safety and effectiveness have not been established.

Source: Dupixent prescribing information

▸How well did Dupixent work in the bullous pemphigoid trial?

In ADEPT, 18.3% on Dupixent reached sustained remission at week 36 against 6.1% on placebo, with everyone also on tapering steroids[1].

Uncertainty: the label's 95% confidence interval for the 12.2-point difference runs from -0.8 to 26.1, which includes no difference.

Itch: 38.3% against 10.5% had at least a 4-point drop on a 0 to 10 scale.

Steroids: the median total steroid dose by week 36 was 2.8g against 4.1g.

Rescue treatment: 53% against 79%.

Source: Dupixent prescribing information

▸Dupixent side effects in EoE and bullous pemphigoid

Side effects differ by disease, and eye inflammation was more common in the bullous pemphigoid trial than in the EoE trials[1].

EoE: injection site reactions 38% against 33% on placebo, upper respiratory infections 18% against 10%.

Bullous pemphigoid: joint pain 9% against 6%, conjunctivitis 8%, blurred vision 8% and keratitis 4%, against 0% on placebo.

Eye symptoms: the label asks patients to report new or worse eye symptoms.

Boxed warning: none.

Source: Dupixent prescribing information

▸Is there a Dupixent copay card?

Yes. Through DUPIXENT MyWay, eligible commercially insured patients may pay as little as $0 per fill, up to $13,000 per calendar year[14].

Not eligible: prescriptions paid in any part by Medicaid, Medicare, VA, DOD, TRICARE or other federal or state programs.

No insurance or trouble paying: the DUPIXENT MyWay Patient Assistance Program reviews each case, including people with Medicare Part D.

Phone: 1-844-DUPIXENT (1-844-387-4936), option 1, Monday to Friday, 8 AM to 9 PM ET.

Source: DUPIXENT MyWay

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Sanofi-Aventis U.S. LLC via DailyMed · 2026-04-22. DUPIXENT- dupilumab injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780
  2. U.S. Food and Drug Administration · 2017-03-28. DUPIXENT approval history, BLA 761055. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
  3. Sanofi · 2022-05-20. FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis. https://www.sanofi.com/en/media-room/press-releases/2022/2022-05-20-19-15-00-2447906
  4. Sanofi · 2024-01-25. Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE). https://www.sanofi.com/en/media-room/press-releases/2024/2024-01-25-19-30-00-2817342
  5. Sanofi · 2025-06-20. Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid. https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-20-05-00-00-3102518
  6. ClinicalTrials.gov. Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE). https://clinicaltrials.gov/study/NCT03633617
  7. ClinicalTrials.gov. Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE). https://clinicaltrials.gov/study/NCT04394351
  8. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid. https://clinicaltrials.gov/study/NCT04206553
  9. ClinicalTrials.gov. Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.. https://clinicaltrials.gov/study/NCT07358234
  10. Takeda Pharmaceuticals America, Inc. via DailyMed · 2025-02-06. EOHILIA (BUDESONIDE) SUSPENSION. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56f2023a-69b2-4470-b4ad-af7ec1be527a
  11. Gastroenterology · 2020-05. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis.. https://pubmed.ncbi.nlm.nih.gov/32359562/
  12. National Organization for Rare Disorders. Bullous Pemphigoid Treatment, Causes, & Symptoms | NORD. https://rarediseases.org/rare-diseases/bullous-pemphigoid/
  13. Sanofi and Regeneron. DUPIXENT MyWay® Copay Card & Insurance | DUPIXENT® (dupilumab). https://www.dupixent.com/support-savings/cost-insurance
  14. Sanofi and Regeneron. What are the eligibility requirements for the DUPIXENT MyWay Copay Card. https://www.dupixent.com/crswnp/FAQ-tabs/FAQs-About-DUPIXENT---dupilumab--for-Nasal-Polyps/What-are-the-eligibility-requirements-for-the-DUPIXENT-MyWay-Copay-Card

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Dupixent by email

We'll email you when Dupixent's FDA label changes, when the FDA acts on it, and when new trials for the condition you pick open. Unsubscribe anytime.

You'll get, for Eosinophilic Esophagitis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site